Family history, genetics play growing role in leukemia screening December 07, 2016 By Bryant Furlow Inherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment. Gene therapy could be ‘ultimate solution’ for sickle cell disease December 07, 2016 By Bryant Furlow Investigational gene therapies might reduce the suffering and death caused by this genetic disease. Large variety of multiple myeloma treatment options presents challenges December 06, 2016 By Bryant Furlow There now exist numerous treatment options for multiple myeloma but how best to sequence them is still under study Top barriers to fully utilizing precision medicine biomarkers December 06, 2016 By Bryant Furlow As development of molecular biomarkers hastens, administrators, clinicians and regulators are working to organize and define biomarkers’ appropriate roles in clinical care—and discussing how to efficiently share the massive amounts of genomic data that will result. Promising treatment developments in lymphoma immunotherapies December 05, 2016 By Bryant Furlow In this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future. Top problems with EHRs and emerging risks jeopardize care quality December 05, 2016 By Bryant Furlow An ASH presenter describes how better health IT and better institutional practices are necessary to leverage EHRs for quality of care. Novel immunotherapies for leukemia could raise life-threatening syndrome December 05, 2016 By Bryant Furlow Novel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome. Hodgkin lymphoma: First hematologic cancer cured with immunotherapy? December 05, 2016 By Bryant Furlow Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more. Top 10 sessions to attend at ASH 2016 November 17, 2016 By Aubrey Westgate This year’s American Society of Hematology (ASH) Conference, held in San Diego, will feature a wide array of sessions.